Hyperpolarized Gas MRI for Bronchopulmonary Dysplasia
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the treatment MagniXene, hyperpolarized 129Xe MRI, for bronchopulmonary dysplasia?
The research suggests that hyperpolarized 129Xe MRI is a promising technique for evaluating lung function in children without using harmful radiation. It has been used to understand lung diseases like asthma and cystic fibrosis, indicating its potential usefulness in assessing and managing bronchopulmonary dysplasia.12345
Is hyperpolarized 129Xe MRI safe for use in humans?
How is hyperpolarized gas MRI different from other treatments for bronchopulmonary dysplasia?
Hyperpolarized gas MRI is unique because it uses special gases like helium-3 and xenon-129 to create detailed images of the lungs without using harmful radiation. This allows doctors to see how well the lungs are working and to track changes over time, which is especially useful for children with lung conditions like bronchopulmonary dysplasia.12378
What is the purpose of this trial?
Hyperpolarized (HP) gas magnetic resonance imaging (MRI) of the lungs offers additional information that cannot be obtained with CT scan, the current gold standard for imaging this disorder. As a nonionizing technique, MRI is an ideal modality for pulmonary imaging; in particular in the infant and pediatric population. Nevertheless, due to the low proton density of the lung parenchyma (only \~20% that of solid tissues), numerous air-tissue interfaces that lead to rapid signal decay, and cardiac and respiratory sources of motion that further degrade image quality , MRI has played a limited role in the evaluation of lung pathologies. In this setting, HP gas (using 129Xe) MRI may play a role in helping determine the regional distribution of alveolar sizes, partial pressure of oxygen, alveolar wall thickness, and gas transport efficiency of the microvasculature within the lungs of infants with a diagnosis of bronchopulmonary dysplasia (BPD).
Research Team
David M Biko, MD
Principal Investigator
Children's Hospital of Philadelphia
Eligibility Criteria
This trial is for infants in the NICU at Children's Hospital of Philadelphia with bronchopulmonary dysplasia (BPD), who are on mechanical ventilation and already receiving sedation. Infants considered unstable for transport to MRI by their primary care team cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo hyperpolarized 129-Xenon MR imaging and conventional proton MR imaging of the lung
Follow-up
Participants are monitored for safety and effectiveness after imaging
Treatment Details
Interventions
- MagniXene, hyperpolarized 129Xe MRI
Find a Clinic Near You
Who Is Running the Clinical Trial?
Xemed LLC
Lead Sponsor
Children's Hospital of Philadelphia
Collaborator